5 stories mentioning SHE:000739Updated 17d ago
Every FINWIRES story that references SHE:000739, newest first.
Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Kangyu Pharmaceutical, received a certificate of suitability from the European Union for its amantadine hydrochloride, according to a Shenzhen bourse filing on Friday.The drug is used to treat symptoms caused by influenza A virus infection, as well as Parkinson's Disease.
The U.S. Food and Drug Administration approved Apeloa Pharmaceutical's (SHE:000739) metoprolol succinate extended-release tablets, according to a Friday disclosure to the Shenzhen bourse.The drug is indicated for hypertension and angina pectoris or chest pain, as well as symptomatic stable chronic heart failure with dysfunction in the left ventricle, among others.
China's drug regulator approved the cefpodoxime proxetil raw material produced by Apeloa Pharmaceutical (SHE:000739) Zhejiang subsidiary, according to a Saturday filing with the Shenzhen bourse.The ingredient is an antibiotic, suited for upper and lower respiratory tract infections, uncomplicated urinary tract infections, and other bacterial infections, the filing said.
Apeloa Pharmaceutical (SHE:000739) posted first-quarter attributable net profit of 249.0 million yuan, up 0.2% from 248.5 million yuan the previous year.Earnings per share rose to 0.2152 yuan from 0.2126 yuan, according to a Tuesday filing with the Shenzhen bourse.Operating revenue declined 10% year over year to 2.45 billion yuan from 2.73 billion yuan.Shares of the pharmaceutical company were up 4% in recent trade.
China's drug regulator approved Apeloa Pharmaceutical's (SHE:000739) registration for its fluvastatin sodium extended-release tablets, according to a Thursday filing with the Shenzhen bourse.Fluvastatin sodium is indicated for cholesterol lowering, the filing said.
